奥扎格雷联合尤瑞克林治疗急性脑梗死的临床疗效

Clinical Efficacy of Ozagrel Combined with Urinary Kallidinogenase in the Treatment of Acute Cerebral Infarction

目的 探讨奥扎格雷联合尤瑞克林在急性脑梗死患者治疗当中的临床疗效。方法 回顾性分析盘锦市中心医院神经内科病区从2020年1月至2020年10月收入的86例急性脑梗死患者的临床资料。并将86例急性脑梗死患者按照随机法分为两组,对照组和观察组各43例。所有患者均给予基础治疗。对照组应用奥扎格雷治疗,观察组在对照组的基础上加用尤瑞克林治疗。采用NIHSS评分(神经功能缺损评分)及ADL评分(日常生活能力评分),分别对两组患者治疗前及治疗2周后的神经功能及日常生活能力进行评估。并用NIHSS评分的下降程度评估脑梗死患者的临床治疗效果。结果 86例患者,其中男性49例,女性37例,年龄20~83岁,平均年龄(65.32±5.17)岁。在NIHSS评分方面,治疗前观察组的患者NIHSS评分为(15.73±5.24)分,对照组的患者NIHSS评分为(16.34±4.81)分;治疗后观察组的患者NIHSS评分为(4.89±2.02)分,对照组的患者NIHSS评分为(8.24±2.55)分。治疗后观察组患者和对照组患者NIHSS评分均较治疗前显著降低(P <0.05),差异具有统计学意义。在ADL评分方面,治疗前观察组的患者ADL评分为(33.58±8.83)分,对照组的患者ADL评分为(35.74±7.11)分;治疗后观察组的患者的ADL评分为(69.82±12.18)分,对照组的患者的ADL评分为(48.89±6.02)分。治疗后观察组患者和对照组患者的ADL评分较治疗前显著升高,差异具有统计学意义。观察组患者的总有效率为95.35%(41/43),显著高于对照组[74.42%(32/42)](P<0.05)。并且两组患者均未发生其他系统明显不良反应,肝肾功能、血常规、尿常规、血离子、心电图等动态监测未发生明显异常。结论 奥扎格雷联合尤瑞克林治疗急性脑梗死疗效显著,可以明显的改善脑梗死患者预后,而且安全可靠,值得在临床范围内推广及进一步的深入研究。

Objective To investigate the clinical efficacy of ozagrel combined with urinary kallidinogenase in the treatment of patients with acute cerebral infarction. Methods The clinical data of 86 patients with cerebral infarction who were admitted from January 2020 to October 2020 in the neurology ward of Panjin Central Hospital were retrospectively analyzed. The 86 patients with acute cerebral infarction were randomly divided into two groups, with 43 cases in the control group and the observation group. All patients were given basic treatment. The control group was treated with ozagrel, and the observation group was treated with urinary kallidinogenase on the basis of the control group. The NIHSS score(neural impairment score) and ADL score(activity of daily living score) were used to evaluate the neurological function and ability of daily living of the two groups of patients before treatment and after 2 weeks of treatment. The decrease of NIHSS score was used to evaluate the clinical treatment effect of patients with cerebral infarction. Result Eighty-six patients, including 49 males and 37 females, were 20-83 years old, with an average age of(65.32±5.17) years old. In terms of NIHSS score, the NIHSS score of patients in the observation group before treatment was(15.73±5.24) points, and the NIHSS score of patients in the control group before treatment was(16.34±4.81) points;the NIHSS score of patients in the observation group after treatment was(4.89±2.02) points, the NIHSS score of patients in the control group after treatment was(8.24±2.55) points. After treatment, the NIHSS scores of the observation group and the control group were significantly lower than before treatment(P<0.05), and the difference was statistically significant. In terms of ADL score, the ADL score of patients in the observation group before treatment was(33.58±8.83) points, and the ADL score of patients in the control group before treatment was(35.74±7.11) points;the ADL score of patients in the observation group after treatment was(69.82±12.18) points.After treatment, the ADL score of patients in the control group was(48.89±6.02) points. After treatment, the ADL scores of the observation group and the control group were significantly higher than those before treatment, and the difference was statistically significant. The total effective rate of patients in the observation group was 95.35%(41/43), which was significantly higher than that in the control group [74.42%(32/42)](P<0.05).In addition, there were no obvious adverse reactions of other systems in the two groups of patients. There were no obvious abnormalities in the dynamic monitoring of liver function, kidney function, blood routine, urine routine, ion, electrocardiogram and so on. Conclusion Ozagrel combined with urinary kallidinogenase has a significant effect in the treatment of acute cerebral infarction, which can significantly improve the prognosis of patients with cerebral infarction, and is safe and reliable. It is worthy of clinical promotion and further in-depth research.